Novan Inc
F:6LUA
Novan Inc
Accounts Receivables
Novan Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Accounts Receivables
$22m
|
CAGR 3-Years
274%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Receivables
$17.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Receivables
$9.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Receivables
$14.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Receivables
$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Receivables
$16.1B
|
CAGR 3-Years
33%
|
CAGR 5-Years
22%
|
CAGR 10-Years
16%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Accounts Receivables?
Accounts Receivables
22m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Accounts Receivables amounts to 22m USD.
What is Novan Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
274%
Over the last year, the Accounts Receivables growth was 392%. The average annual Accounts Receivables growth rates for Novan Inc have been 274% over the past three years .
